摘要
急性髓系白血病(AML)是第一个恶性肿瘤的免疫治疗,以异基因造血干细胞移植(allo-HSCT)的形式,被整合到标准的护理。异基因造血干细胞移植的不过是一个具有显著的发病率和死亡率的不完美的治疗,而只提供不完全预防白血病复发。这些限制促使寻找白血病相关抗原,可作为免疫治疗更具针对性和有效性的目标。而历史上这样的研究都集中在唯一的急性髓系白血病或显着较高的水平比在正常组织中表达的蛋白靶点,本文将回顾最近的研究发现了一种新的潜在的靶抗原的白血病免疫治疗的选择,如非蛋白的目标包括脂类和碳水化合物,新抗原基因的体细胞突变或改变剪接和蛋白质翻译后修饰的创建目标,结合创新的方式表达的蛋白靶点的靶细胞表面抗原肽-MHC复合物。这些新的抗原表现出有前途的候选人的进一步发展为急性髓系白血病的治疗目标。
关键词: 急性髓系白血病,抗原,免疫治疗
Current Drug Targets
Title:Novel Antigen Targets for Immunotherapy of Acute Myeloid Leukemia
Volume: 18 Issue: 3
Author(s): Meghali Goswami, Christopher S. Hourigan.
Affiliation:
关键词: 急性髓系白血病,抗原,免疫治疗
摘要: Acute myeloid leukemia (AML) was the first malignancy for which immunotherapy, in the form of allogeneic hematopoietic stem cell transplantation (allo-HSCT), was integrated into the standard of care. Allo-HSCT however is an imperfect therapy associated with significant morbidity and mortality while offering only incomplete prevention of AML clinical relapse. These limitations have motivated the search for AML-related antigens that might be used as more specific and effective targets of immunotherapy. While historically such investigations have focused on protein targets expressed uniquely in AML or at significantly higher levels than in normal tissues, this article will review recent discoveries which have identified a novel selection of potential antigen targets for AML immunotherapy, such as non-protein targets including lipids and carbohydrates, neo-antigens created from genetic somatic mutations or altered splicing and post-translational modification of protein targets, together with innovative ways to target overexpressed protein targets presented by cell surface peptide-MHC complexes. These novel antigens represent promising candidates for further development as targets of AML immunotherapy.
Export Options
About this article
Cite this article as:
Meghali Goswami, Christopher S. Hourigan. , Novel Antigen Targets for Immunotherapy of Acute Myeloid Leukemia, Current Drug Targets 2017; 18 (3) . https://dx.doi.org/10.2174/1389450116666150223120005
DOI https://dx.doi.org/10.2174/1389450116666150223120005 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
MicroRNAs in the Intracellular Space, Regulation of Organelle Specific Pathways in Health and Disease
MicroRNA Natural Antibodies: Protecting Role of IgM in Glioblastoma and Brain Tumours
Current Pharmaceutical Design On Therapeutic Drug Monitoring of Thiopurines in Inflammatory Bowel Disease; Pharmacology, Pharmacogenomics, Drug Intolerance and Clinical Relevance
Current Drug Metabolism The TGF-β Signaling Pathway as a Pharmacological Target in a Hepatocellular Carcinoma
Current Pharmaceutical Design Subcellular Detection and Localization of the Drug Transporter P-Glycoprotein in Cultured Tumor Cells
Current Protein & Peptide Science Antiangiogenesis in Myelodysplastic Syndrome
Current Cancer Drug Targets Apoptosis in Anthracycline Cardiomyopathy
Current Pediatric Reviews A Comparison of Physicochemical Property Profiles of Marketed Oral Drugs and Orally Bioavailable Anti-Cancer Protein Kinase Inhibitors in Clinical Development
Current Topics in Medicinal Chemistry New Hopes in Cancer Battle - A Review of New Molecules and Treatment Strategies
Medicinal Chemistry Anticancer and Reversing Multidrug Resistance Activities of Natural Isoquinoline Alkaloids and their Structure-activity Relationship
Current Medicinal Chemistry Metallothioneins and Cancer
Current Protein & Peptide Science Natural Products Based Anticancer Agents
Mini-Reviews in Organic Chemistry Functional and Clinical Significance of the Integrin Alpha Chain CD49d Expression in Chronic Lymphocytic Leukemia
Current Cancer Drug Targets Activated Cancer Therapy Using Light and Ultrasound - A Case Series of Sonodynamic Photodynamic Therapy in 115 Patients Over a 4 Year Period
Current Drug Therapy Characterization of the Early CNS Stress Biomarkers and Profiles Associated with Neuropsychiatric Diseases
Current Genomics Novel Agents Aiming at Specific Molecular Targets Increase Chemosensitivity and Overcome Chemoresistance in Hematopoietic Malignancies
Current Pharmaceutical Design Comprehensive DNA Methylation-transcriptome Profiles Association Analysis During the Treatment of Acute Myelocytic Leukemia
Current Pharmaceutical Design Clinical Significance of Breast Cancer Resistance Protein/ABCG2 in the Management of Malignancy
Clinical Cancer Drugs Interferon-Beta Therapy Monitoring in Multiple Sclerosis Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets Advances in DNA-Ligands with Groove Binding, Intercalating and/or Alkylating Activity: Chemistry, DNA-Binding and Biology
Current Medicinal Chemistry